Guest: Lars Fruergaard Jørgensen CEO of Novo Nordisk
“I'm very concerned that European citizens will have lack of access or much lower access to some of the new medicines”, says CEO of Novo Nordisk to Nicolai Tangen. Lars Fruergaard Jørgensen also shares some interesting perspectives about the importance of purpose and Novo Nordisk's new weight loss drug Wegovy.
The fund's investments in Novo Nordisk
At the end of 2022, the fund's investments in Novo Nordisk had a market value of 57.1 billion kroner or 5.8 billion dollar.
The production team on this episode were PLAN-B’s Nikolai Ovenberg and Niklas Figenschaug Johansen. Background research was done by Sigurd Brekke with additional input from our portfolio manager Gemma Game.
Last saved: 15/03/2023